Azure Synthetics Azure Synthetics Research peptides, clearly documented.
RU
Корзина 0 Browse catalog
Tirzepatide

Metabolic research

Tirzepatide

Lyophilized metabolic research compound

Tirzepatide is a dual GIP / GLP-1 receptor agonist reference point in metabolic research and comparative incretin pharmacology.

Диапазон цен: 104.99 $ – 930.99 $
98.8%-99.5% Лиофилизированный порошок 30 mg
Available certificate of analysis

This product has an available COA with reported batch details and test results.

Open available COA

For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.

Storage

Храните в закрытом, холодном, сухом месте и защищенном от перепадов температур. По прибытии подтвердите хранение конкретного продукта.

Отгрузочные накладные

Упаковано для обеспечения стабильности транспортировки, поддержка заказов доступна для маршрутов в теплую погоду.

Batch reference

Batch-linked certificate support is available through the documentation desk.

Контекст исследования

Исследовательский профиль Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist used extensively in incretin and metabolic pharmacology research. Experimental work examines receptor activation, cyclic-AMP signaling, receptor balance, pharmacokinetics, glucose regulation, lipid markers, and downstream metabolic endpoints. It is commonly compared with GLP-1-only compounds and with newer multi-receptor molecules such as retatrutide. Buyers typically select tirzepatide when the study design specifically needs a well-characterized dual-incretin reference without glucagon-receptor activity. A large human literature exists for the pharmaceutical molecule, but those findings do not verify the composition, sterility, safety, or performance of a separate research-use product.

Предполагаемый механизм

Dual agonism at GIPR and GLP-1R, two class B G-protein-coupled receptors that signal largely through cyclic AMP. Proposed effects include glucose-dependent insulin secretion, altered glucagon signaling, delayed gastric emptying through GLP-1 pathways, and central appetite-related signaling.

Эффекты, описанные в исследованиях

  • Receptor and animal studies report enhanced incretin signaling, improved glucose control, reduced food intake, and reduced body mass.
  • Controlled human trials reported substantial reductions in glycated hemoglobin and body weight across studied populations.
  • Frequently reported study effects include nausea, diarrhea, vomiting, constipation, and other gastrointestinal events.

Типичные исследовательские конечные точки

GIPR and GLP-1R potency, cyclic AMP, insulin and glucagon response, gastric-emptying markers, glucose, HbA1c, lipids, food intake, body mass, pharmacokinetics, and tolerability.

Данные и ограничения

Extensive receptor, animal, and controlled human evidence exists for regulated tirzepatide products. Catalog material is not represented as equivalent to an approved pharmaceutical product.

External reading

Literature for context—not product proof.

Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.

Support and documentation

Questions about this product?

What documentation can I request before ordering?

Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.

What should I confirm before ordering?

Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.

Keep comparing

Compare other catalog records.

Explore related research materials. These are not a combined-use recommendation.